JAMA Cardiology

Article	Citations
Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China	2903
Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)	2806
Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19)	1545
Potential Effects of Coronaviruses on the Cardiovascular System	1304
Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)	1272
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes	615
Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases	612
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)	492
Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality	419
Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China	401
Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military	392
Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)	299
A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia	255
Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination	231
Prevalence of Clinical and Subclinical Myocarditis in Competitive Athletes With Recent SARS-CoV-2 Infection	227
Characteristics Associated With Out-of-Hospital Cardiac Arrests and Resuscitations During the Novel Coronavirus Disease 2019 Pandemic in New York City	207
Prevalence of Inflammatory Heart Disease Among Professional Athletes With Prior COVID-19 Infection Who Received Systematic Return-to-Play Cardiac Screening	197
Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Car	187
Cardiovascular Magnetic Resonance Findings in Competitive Athletes Recovering From COVID-19 Infection	183
Utility of a Deep-Learning Algorithm to Guide Novices to Acquire Echocardiograms for Limited Diagnostic Use	162
Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers	162
A Game Plan for the Resumption of Sport and Exercise After Coronavirus Disease 2019 (COVID-19) Infection	161
The Dilemma of Coronavirus Disease 2019, Aging, and Cardiovascular Disease	156
Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi	155
Coronavirus Disease 2019 and the Athletic Heart	152

Evaluation for Myocarditis in Competitive Student Athletes Recovering From Coronavirus Disease 2019 With Cardiac Magnetic Resonance Imaging	149
Association of Monogenic vs Polygenic Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease	142
Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease 2019	139
Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children	134
Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019	134
Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome	126
TET2-Driven Clonal Hematopoiesis and Response to Canakinumab	124
Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure—Optimizing Therapy With the Need for Speed	124
Association of Normal Systolic Blood Pressure Level With Cardiovascular Disease in the Absence of Risk Factors	123
Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction	122
Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia	121
Evolving Trends in Adult Heart Transplant With the 2018 Heart Allocation Policy Change	118
Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction	116
SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents	113
Use of Machine Learning Models to Predict Death After Acute Myocardial Infarction	112
Outcomes for Out-of-Hospital Cardiac Arrest in the United States During the Coronavirus Disease 2019 Pandemic	107
Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis	106
Association of Clinical Outcomes With Left Ventricular Assist Device Use by Bridge to Transplant or Destination Therapy Intent	105
One-Year Outcomes of Mitral Valve-in-Valve Using the SAPIEN 3 Transcatheter Heart Valve	105
Screening for Atrial Fibrillation in the Older Population	102
Case Rates, Treatment Approaches, and Outcomes in Acute Myocardial Infarction During the Coronavirus Disease 2019 Pandemic	101
Association of Adverse Childhood Experiences With Cardiovascular Disease Later in Life	98
National Trends in Heart Failure Hospitalizations and Readmissions From 2010 to 2017	98
Association of Sex With Severity of Coronary Artery Disease, Ischemia, and Symptom Burden in Patients With Moderate or Severe Ischemia	98
Development of Persistent Opioid Use After Cardiac Surgery	94
Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction	94
Long-term Outcomes in Patients With Severely Reduced Left Ventricular Ejection Fraction Undergoing Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting	91
Use of Temporary Mechanical Circulatory Support for Management of Cardiogenic Shock Before and After the United Network for Organ Sharing Donor Heart Allocation System Changes	91
Mechanical Complications of Acute Myocardial Infarction	89
Lipoprotein(a) and its Significance in Cardiovascular Disease	86
Association of Clonal Hematopoiesis of Indeterminate Potential With Inflammatory Gene Expression in Patients With Severe Degenerative Aortic Valve Stenosis or Chronic Postischemic Heart Failure	86
Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US	85
Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine–Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis	83
Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women	82
New Evidence Supporting a Novel Conceptual Framework for Distinguishing Proportionate and Disproportionate Functional Mitral Regurgitation	81
Volume-Outcome Association of Mitral Valve Surgery in the United States	81
Myocarditis Occurring After Immunization With mRNA-Based COVID-19 Vaccines	79
Association of Low Socioeconomic Status With Premature Coronary Heart Disease in US Adults	77
Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure	77
Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction	74
Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials	73
Complete vs Culprit-Lesion-Only Revascularization for ST-Segment Elevation Myocardial Infarction	72
Multichannel Electrocardiograms Obtained by a Smartwatch for the Diagnosis of ST-Segment Changes	72
Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial	71
An Acute Respiratory Infection Runs Into the Most Common Noncommunicable Epidemic—COVID-19 and Cardiovascular Diseases	71
Association Between Cumulative Low-Density Lipoprotein Cholesterol Exposure During Young Adulthood and Middle Age and Risk of Cardiovascular Events	70
Association Between High-Density Lipoprotein Cholesterol Levels and Adverse Cardiovascular Outcomes in High-risk Populations	69
Cardiovascular Health Trajectories From Childhood Through Middle Age and Their Association With Subclinical Atherosclerosis	69
Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction	67
Early-Onset Atrial Fibrillation and the Prevalence of Rare Variants in Cardiomyopathy and Arrhythmia Genes	67

Association of Statin Treatment With Progression of Coronary Atherosclerotic Plaque Composition	67
Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention	66
Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction	65
High-Throughput Precision Phenotyping of Left Ventricular Hypertrophy With Cardiovascular Deep Learning	64
An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial	64
Use of Artificial Intelligence and Deep Neural Networks in Evaluation of Patients With Electrocardiographically Concealed Long QT Syndrome From the Surface 12-Lead Electrocardiogram	64
Remote Optimization of Guideline-Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction	63
Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor–Associated Myocarditis	63
Posttraumatic Stress Disorder and Cardiovascular Disease	62
Association of Adverse Pregnancy Outcomes With Risk of Atherosclerotic Cardiovascular Disease in Postmenopausal Women	62
Performance of a Convolutional Neural Network and Explainability Technique for 12-Lead Electrocardiogram Interpretation	61
Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease	61
Coronary Angiography After Cardiac Arrest Without ST Segment Elevation	61
Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction	60
Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease	60
Effectiveness of Home-Based Mobile Guided Cardiac Rehabilitation as Alternative Strategy for Nonparticipation in Clinic-Based Cardiac Rehabilitation Among Elderly Patients in Europe	60
Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure	59
Association of the Duration of Ideal Cardiovascular Health Through Adulthood With Cardiometabolic Outcomes and Mortality in the Framingham Offspring Study	59
Assessment of Neutrophil Extracellular Traps in Coronary Thrombus of a Case Series of Patients With COVID-19 and Myocardial Infarction	58
Early Mortality in Type A Acute Aortic Dissection	58
Assessment of Catheter Ablation or Antiarrhythmic Drugs for First-line Therapy of Atrial Fibrillation	58
Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure	57
Short-term and Long-term Feasibility, Safety, and Efficacy of High-Intensity Interval Training in Cardiac Rehabilitation	56
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction	56
Association Between Preterm Birth and Arrested Cardiac Growth in Adolescents and Young Adults	56
Trends in US Heart Transplant Waitlist Activity and Volume During the Coronavirus Disease 2019 (COVID-19) Pandemic	56
Rationale and Design of the Aspirin Dosing—A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial	55
Contemporaneous Comparison of Outcomes Among Patients Implanted With a Leadless vs Transvenous Single-Chamber Ventricular Pacemaker	55
Identification of Susceptibility Loci for Spontaneous Coronary Artery Dissection	54
Association of Age With the Diagnostic Value of Coronary Artery Calcium Score for Ruling Out Coronary Stenosis in Symptomatic Patients	53
Stress Myocardial Perfusion Imaging vs Coronary Computed Tomographic Angiography for Diagnosis of Invasive Vessel-Specific Coronary Physiology	53
Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease	53
Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk	52
Coronavirus Disease 2019 (COVID-19) and the Heart—Is Heart Failure the Next Chapter?	52
Survival on the Heart Transplant Waiting List	52
Sex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion	49
Association of Effective Regurgitation Orifice Area to Left Ventricular End-Diastolic Volume Ratio With Transcatheter Mitral Valve Repair Outcomes	49
Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation	49
Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event	49
Clinical Utility of Lipoprotein(a) and LPA Genetic Risk Score in Risk Prediction of Incident Atherosclerotic Cardiovascular Disease	49
Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy	49
Interpretation of the Seattle Angina Questionnaire as an Outcome Measure in Clinical Trials and Clinical Care	49
Global Differences in Characteristics, Precipitants, and Initial Management of Patients Presenting With Acute Heart Failure	49
Emergency vs Delayed Coronary Angiogram in Survivors of Out-of-Hospital Cardiac Arrest	48
Magnetic Resonance Imaging in Patients With Cardiac Implantable Electronic Devices With Abandoned Leads	48
Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Hear	47
Assessment of Coronary Artery Calcium Scoring to Guide Statin Therapy Allocation According to Risk-Enhancing Factors	47
Diastolic Heart Failure in Patients With the Fontan Circulation	45
Interventions to Mitigate Risk of Cardiovascular Disease After Adverse Pregnancy Outcomes	45
Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction	45
Temporal Association Between Episodes of Atrial Fibrillation and Risk of Ischemic Stroke	45
Trends in Mechanical Support Use as a Bridge to Adult Heart Transplant Under New Allocation Rules	45
Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome	44
Diagnosis of Heart Failure With Preserved Ejection Fraction Among Patients With Unexplained Dyspnea	44
Association of Diet Quality With Prevalence of Clonal Hematopoiesis and Adverse Cardiovascular Events	43
Efficacy of Telmisartan to Slow Growth of Small Abdominal Aortic Aneurysms	43
Long-term Results of Differentiated Anatomic Reconstruction of Bicuspid Aortic Valves	43
Effect of Exercise Training on Ambulatory Blood Pressure Among Patients With Resistant Hypertension	41
Self-expanding Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients	41
Association Between Malignant Mitral Valve Prolapse and Sudden Cardiac Death	40
Combined Cardiac Fluorodeoxyglucose–Positron Emission Tomography/Magnetic Resonance Imaging Assessment of Myocardial Injury in Patients Who Recently Recovered From COVID-19	40
Long-term Outcomes Associated With Total Arterial Revascularization vs Non–Total Arterial Revascularization	40
Effect of Personalized Accelerated Pacing on Quality of Life, Physical Activity, and Atrial Fibrillation in Patients With Preclinical and Overt Heart Failure With Preserved Ejection Fraction	39
Fundamental Pathobiology of Coronary Atherosclerosis and Clinical Implications for Chronic Ischemic Heart Disease Management—The Plaque Hypothesis	38
Racial, Ethnic, and Socioeconomic Disparities in Access to Transcatheter Aortic Valve Replacement Within Major Metropolitan Areas	37
Therapeutic Targeting of Left Atrial Myopathy in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction	37
Association of Socioeconomic Disadvantage With Long-term Mortality After Myocardial Infarction	36
Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery	36
Differences in Long-term Outcomes After Coronary Artery Bypass Grafting Using Single vs Multiple Arterial Grafts and the Association With Sex	36
Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction	36
Association of Left Ventricular Systolic Dysfunction Among Carriers of Truncating Variants in Filamin C With Frequent Ventricular Arrhythmia and End-stage Heart Failure	36
Assessing the Role of Rare Genetic Variation in Patients With Heart Failure	36
Association Between Visit-to-Visit Blood Pressure Variability in Early Adulthood and Myocardial Structure and Function in Later Life	35
Catheter-Directed Thrombolysis vs Anticoagulation in Patients With Acute Intermediate-High–risk Pulmonary Embolism	35
Natural History of Asymptomatic Severe Aortic Stenosis and the Association of Early Intervention With Outcomes	35
Apolipoprotein B vs Low-Density Lipoprotein Cholesterol and Non–High-Density Lipoprotein Cholesterol as the Primary Measure of Apolipoprotein B Lipoprotein-Related Risk	34
Association of Blood Pressure Patterns in Young Adulthood With Cardiovascular Disease and Mortality in Middle Age	34
Association of Damaging Variants in Genes With Increased Cancer Risk Among Patients With Congenital Heart Disease	34
Association Between Reproductive Life Span and Incident Nonfatal Cardiovascular Disease	33
The Clinical Challenge of Clonal Hematopoiesis, a Newly Recognized Cardiovascular Risk Factor	33

Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction	33
Association of Circulating Monocyte Chemoattractant Protein–1 Levels With Cardiovascular Mortality	33
An Appraisal of the Association of Clinical Outcomes With the Severity of Regurgitant Volume Relative to End-Diastolic Volume in Patients With Secondary Mitral Regurgitation	33
Association of Sitting Time With Mortality and Cardiovascular Events in High-Income, Middle-Income, and Low-Income Countries	33
Structural Valve Deterioration After Self-Expanding Transcatheter or Surgical Aortic Valve Implantation in Patients at Intermediate or High Risk	32
Percutaneous Intramyocardial Septal Radiofrequency Ablation in Patients With Drug-Refractory Hypertrophic Obstructive Cardiomyopathy	32
Association of Ascending Aortic Dilatation and Long-term Endurance Exercise Among Older Masters-Level Athletes	32
Transplant Center Variability in Organ Offer Acceptance and Mortality Among US Patients on the Heart Transplant Waitlist	32
Association of Posttraumatic Stress Disorder and Incident Ischemic Heart Disease in Women Veterans	31
Comparison of Long-term Clinical Outcomes of Skeletonized vs Pedicled Internal Thoracic Artery Harvesting Techniques in the Arterial Revascularization Trial	31
Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control	31
Association of Rare Genetic Variants and Early-Onset Atrial Fibrillation in Ethnic Minority Individuals	31
Machine Learning–Based Models Incorporating Social Determinants of Health vs Traditional Models for Predicting In-Hospital Mortality in Patients With Heart Failure	30
Individualized Studies of Triggers of Paroxysmal Atrial Fibrillation	30
Association of FADS1/2 Locus Variants and Polyunsaturated Fatty Acids With Aortic Stenosis	30
Exercise Electrocardiography and Computed Tomography Coronary Angiography for Patients With Suspected Stable Angina Pectoris	30
Association of Pediatric Obstructive Sleep Apnea With Elevated Blood Pressure and Orthostatic Hypertension in Adolescence	30
The Learning Curve for Shared Decision-making in Symptomatic Aortic Stenosis	30
Clinical and Functional Characterization of Ryanodine Receptor 2 Variants Implicated in Calcium-Release Deficiency Syndrome	29
Objective Risk Assessment vs Standard Care for Acute Coronary Syndromes	29
Association of Differences in Treatment Intensification, Missed Visits, and Scheduled Follow-up Interval With Racial or Ethnic Disparities in Blood Pressure Control	28
Derivation and Validation of a 4-Level Clinical Pretest Probability Score for Suspected Pulmonary Embolism to Safely Decrease Imaging Testing	28
Assessment of Long-term Benefit of Intensive Blood Pressure Control on Residual Life Span	28
Association of Atrial Fibrillation Burden With Health-Related Quality of Life After Atrial Fibrillation Ablation	28
Trends in the Prevalence of Self-reported Heart Failure by Race/Ethnicity and Age From 2001 to 2016	28
Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention	28
Disproportionate Emphasis on Proportionate Mitral Regurgitation—Are There Better Measures of Regurgitant Severity?	27
Guideline Update on Indications for Transcatheter Aortic Valve Implantation Based on the 2020 American College of Cardiology/American Heart Association Guidelines for Management of Valvular Heart Dise	27
Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines	27
Association of Echocardiographic Left Ventricular End-Systolic Volume and Volume-Derived Ejection Fraction With Outcome in Asymptomatic Chronic Aortic Regurgitation	27
Demographic and Regional Trends of Heart Failure–Related Mortality in Young Adults in the US, 1999-2019	27
Associations of Adiposity, Circulating Protein Biomarkers, and Risk of Major Vascular Diseases	27
Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With β-Blockers	27
Assessment of the Diagnostic Yield of Combined Cardiomyopathy and Arrhythmia Genetic Testing	26
Trends in Readmission and Mortality Rates Following Heart Failure Hospitalization in the Veterans Affairs Health Care System From 2007 to 2017	26
Results of a Remotely Delivered Hypertension and Lipid Program in More Than 10 000 Patients Across a Diverse Health Care Network	26
Association of Systolic Blood Pressure Elevation With Disproportionate Left Ventricular Remodeling in Very Preterm-Born Young Adults	26
Alerting Clinicians to 1-Year Mortality Risk in Patients Hospitalized With Heart Failure	26
Long-term Clinical and Echocardiographic Outcomes in Young and Middle-aged Adults Undergoing the Ross Procedure	26
Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US	26
Prediction of Pulmonary to Systemic Flow Ratio in Patients With Congenital Heart Disease Using Deep Learning–Based Analysis of Chest Radiographs	26
Association of Rare PTGIS Variants With Susceptibility and Pulmonary Vascular Response in Patients With Idiopathic Pulmonary Arterial Hypertension	26
Hybrid Positron Emission Tomography/Magnetic Resonance Imaging in Arrhythmic Mitral Valve Prolapse	26
Long-term Benefits and Harms Associated With Genetic Cholesteryl Ester Transfer Protein Deficiency in the General Population	26
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes	26
State of the Nation’s Cardiovascular Health and Targeting Health Equity in the United States	25
Return to Play for Athletes After COVID-19 Infection	25
Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation	25
Strategies of Wait-listing for Heart Transplant vs Durable Mechanical Circulatory Support Alone for Patients With Advanced Heart Failure	25
Transcatheter Aortic Valve Replacement in Low-risk Patients With Bicuspid Aortic Valve Stenosis	25
Cardiovascular Biomarkers in the Early Discrimination of Type 2 Myocardial Infarction	25
Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction	25
Associations of High-Sensitivity Troponin and Natriuretic Peptide Levels With Outcomes After Intensive Blood Pressure Lowering	25
A Simple Score to Identify Increased Risk of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction	24
Cardiovascular Magnetic Resonance Imaging Phenotypes and Long-term Outcomes in Patients With Suspected Cardiac Sarcoidosis	24
Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines	24
Sex-Related Disparities in Cardiovascular Health Care Among Patients With Premature Atherosclerotic Cardiovascular Disease	24
Routine Ultrasonography Guidance for Femoral Vascular Access for Cardiac Procedures	24
Predictive Utility of a Coronary Artery Disease Polygenic Risk Score in Primary Prevention	24
Outcomes Associated With Catheter Ablation of Ventricular Tachycardia in Patients With Cardiac Sarcoidosis	23
Quality of Life in Patients With Heart Failure With Recovered Ejection Fraction	23
Association of Financial Hardship Because of Medical Bills With Adverse Outcomes Among Families of Children With Congenital Heart Disease	23
Rare and Common Genetic Variation Underlying the Risk of Hypertrophic Cardiomyopathy in a National Biobank	23
Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials	23
Blood DNA Methylation and Incident Coronary Heart Disease	23
Evaluation of Stress Cardiac Magnetic Resonance Imaging in Risk Reclassification of Patients With Suspected Coronary Artery Disease	23
Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials	23
Fear of Coronavirus Disease 2019—An Emerging Cardiac Risk	22
Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease	22
Remote Cardiac Monitoring in Patients With Heart Failure	22
Association of Genetic West African Ancestry, Blood Pressure Response to Therapy, and Cardiovascular Risk Among Self-reported Black Individuals in the Systolic Blood Pressure Reduction Intervention Tr	22
High-Sensitivity Cardiac Troponin Concentrations at Presentation in Patients With ST-Segment Elevation Myocardial Infarction	22
Association of Non–High-Density Lipoprotein Cholesterol Measured in Adolescence, Young Adulthood, and Mid-Adulthood With Coronary Artery Calcification Measured in Mid-Adulthood	22
Association of Global Longitudinal Strain With Clinical Status and Mortality in Patients With Chronic Heart Failure	22
Cost-effectiveness of Contemporary Statin Use Guidelines With or Without Coronary Artery Calcium Assessment in African American Individuals	22
Sex-Based Outcomes in Patients With a High Bleeding Risk After Percutaneous Coronary Intervention and 1-Month Dual Antiplatelet Therapy	22
Sex and Race Differences in N-Terminal Pro–B-type Natriuretic Peptide Concentration and Absolute Risk of Heart Failure in the Community	22
Genomic Autopsy of Sudden Deaths in Young Individuals	22
Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction	21
Association of Mortality With Aortic Stenosis Severity in Outpatients	21
Long-term Survival After Out-of-Hospital Cardiac Arrest	21
Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction	21
Effectiveness of Systematic Echocardiographic Screening for Rheumatic Heart Disease in Nepalese Schoolchildren	21
Association of Smoking With Postprocedural Complications Following Open and Endovascular Interventions for Intermittent Claudication	20
Initial Experience Prescribing Commercial Tafamidis, the Most Expensive Cardiac Medication in History	20
Feasibility of Remote Video Assessment of Jugular Venous Pressure and Implications for Telehealth	20
Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy	20
Exercise Capacity in Young Adults Born Small for Gestational Age	19
Association of Rurality With Risk of Heart Failure	19
Association of Mitral Annular Disjunction With Cardiovascular Outcomes Among Patients With Marfan Syndrome	19
Effect of Transcutaneous Magnetic Stimulation in Patients With Ventricular Tachycardia Storm	19
Metabolomic Analysis of Coronary Heart Disease in an African American Cohort From the Jackson Heart Study	19
Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US	19
Cardiovascular Functional Reserve Before and After Kidney Transplant	19
Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice	19